Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: Recent experience at Rizzoli Institute

Oncology Reports

Volumn 9, Issue 1, 2002, Pages 171-175

  Bacci, Gaetano ^a   Longhi, Alessandra ^a   Ferrari, Stefano ^a   Lari, Stefano ^a   Manfrini, Marco ^a   Donati, Davide ^a   Forni, Cristiana ^a   Versari, Michela ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Neoadjuvant chemotherapy; Osteosarcoma; Serum alkaline phosphatase

Indexed keywords

ALKALINE PHOSPHATASE;

ADJUVANT THERAPY; ADOLESCENT; AGE; ARTICLE; BLOOD; BONE TUMOR; CANCER STAGING; ENZYMOLOGY; FEMALE; FOLLOW UP; HUMAN; LIMB; MALE; OSTEOSARCOMA; PROGNOSIS; SURVIVAL;

ADOLESCENT; AGE FACTORS; ALKALINE PHOSPHATASE; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; NEOADJUVANT THERAPY; NEOPLASM STAGING; OSTEOSARCOMA; PROGNOSIS;

EID: 0036134519     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.1.171     Document Type: Article

References (39)

1. Campanacci M, Bacci G, Bertoni F, Picci P, Minutillo A and Franceschi C: The treatment of osteosarcoma of the extremities: twenty years experience at the Istituto Ortopedico Rizzoli. Cancer 48: 1569-1581, 1981. (Pubitemid 12199416)
2. Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremities. N Engl J Med 314: 1600-1606, 1986. (Pubitemid 16118216)
3. Picci P, Calderoni P, Cagnano R, Minutillo A, Gherlinzoni F and Bacci G: The hypothetical change in the natural history of osteosarcoma. Chemioterapia 1: 420-427, 1982.
4. Bacci G, Picci P, Ferrari S, et al: Primary chemotherapy and delayed surgery for non-metastatic osteosarcoma of the extremities. Results in 167 patients treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 72: 3227-3238, 1993. (Pubitemid 23356765)
5. Fuchs N, Bielack SS, Epler D, et al: Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 9: 893-899, 1998. (Pubitemid 28440449)
6. Jaffe N, Raymond K, Ayala A, et al: Intraarterial cisdiammine- dichloroplatinum II in pediatric osteosarcoma: relationship of the effect on primary tumor to survival. In: Recent Concepts in Sarcoma Treatment. Ryan JR and Baker O (eds). Kluwer Academic Publisher, Dordrecht, pp275-282, 1988.
7. Meyers PA, Heller G, Healey J, et al: Chemotherapy for non-metastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10: 5-15, 1992.
8. Provisor AJ, Ettinger LJ, Nachmann JB, et al: Treatment of non-metastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 15: 76-84, 1997. (Pubitemid 27020560)
9. Rosen G: Preoperative chemotherapy (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten years experience. Orthopaedics 8: 659-664, 1985.
10. Saeter G, Alvegard TA, Elomaa I, Stenwig AE, Holmstrom T and Solheim OP: Treatment of osteosarcoma of the extremity with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 9: 1766-1775, 1991.
11. Winkler K, Bieling P, Bielack S, et al: Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry. Clin Orthop 270: 79-86, 1991.
12. Bacci G, Ferrari S, Bertoni F, et al: Long-term outcome for patients with non-metastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 18: 4016-4027, 2000. (Pubitemid 32038393)
13. Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E and Solheim OP: Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long-term survival. Cancer 75: 1084-1093, 1995.
14. McKenna RJ, Schwin CP, Soong KJ and Higinbotham NL: Sarcomata of osteogenic series: analysis of 552 cases. J Bone Joint Surg 48: 1-26, 1966.
15. Davis AM, Bell RS and Goodwin PJ: Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 12: 423-431, 1994. (Pubitemid 24056419)
16. Bacci G, Picci P, Ferrari S, et al: Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer 71: 1224-1230, 1993. (Pubitemid 23054910)
17. Bacci G, Picci P, Ruggieri P, et al: Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intra-arterial cisplatin. Cancer 65: 2539-2553, 1990.
18. Bacci G, Ferrari S, Mercuri M, et al: Neoadjuvant chemotherapy for extremity osteosarcoma: preliminary results of the Rizzoli's 4th study. Acta Oncol 37: 41-48, 1998.
19. Ferrari S, Mercuri M, Picci P, et al: Non-metastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol with high dose methotrexate, intra-arterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori 85: 458-464, 1999.
20. Wallach J: Interpretation of Diagnostic Tests. Little Brown and Co., Boston, 1986.
21. Petrelli AS, Gentil FC and Epelman S: Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer 68: 733-737, 1991.
22. Scranton PE, De Cicco FA, Totten RS and Yunis EJ: Prognostic factors in osteosarcoma. Cancer 36: 2179-2191, 1975.
23. Bentzen SM, Poulsen HS, Kaae S, et al: Prognostic factors in osteosarcomas. A regression analysis. Cancer 62: 194-202, 1988.
24. Goorin AM, Perez-Atayde A and Gebhardt M: Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana Farber Cancer Institute/The Children's Hospital-Study III. J Clin Oncol 5: 1178-1184, 1987.
25. Raymond AK, Chawla SP and Carrasco CH: Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol 4: 212-236, 1987.
26. Spanier SS, Shuster JJ and van der Griend RA: The effect of local extent of the tumor on prognosis in osteosarcoma. J Bone Joint Surg 72: 643-654, 1990.
27. Brostrom LA, Strander H and Nilsonne U: Survival in osteosarcoma in relation to tumor size and location. Clin Orthop 167: 250-254, 1982. (Pubitemid 12090669)
28. Glasser DB, Lane JM and Huvos AG: Survival, prognosis and therapeutic response in osteogenic sarcoma. Cancer 69: 698-708, 1992.
29. Larsson SE, Loretzon R, Wedren H and Boquist L: Osteosarcoma. A multifactorial clinical and histopathological study with special regard to therapy and survival. Acta Orthop Scand 49: 571-581, 1978. (Pubitemid 9103835)
30. Lockshin M and Higgins I: Prognosis in osteogenic sarcoma. Clin Orthop 58: 85-103, 1968.
31. Wuisman P, Enneking WF and Roesner A: Local growth and the prognosis of osteosarcoma. Int Orthop 16: 55-58, 1992.
32. Bieling P, Rehan N, Winkler P, et al: Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 14: 848-858, 1996. (Pubitemid 26085530)
33. Baldini N, Scotlandi K, Barbanti-Brodano G, et al: Expression on P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333: 1380-1385, 1995.
34. Eilber F and Caulikins E: Bone tumors: clinical and radiological investigation. In: Current Concepts of Diagnosis and Treatment of Bone and Soft Tissue Tumors. Uhthof HD (ed). Springer-Verlag, Berlin, pp47-53, 1984.
35. Thorpe W, Reilly J and Rosemberg S: Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer 43: 2178-2181, 1979. (Pubitemid 9246384)
36. Singh I, Tsang K and Ludwig G: Alakaline phosphatase and ultrastructural alterations in human osteosarcoma cells in tissue culture. Eur Surg Res 6: 247-263, 1974.
37. Ghanta V, Hiramoto R, Weiss A and Caudill L: Monitoring of murine osteosarcoma by serial alkaline phosphatase determinations. J Natl Cancer Inst 37: 837-839, 1976.
38. Garzotto CK, Berg J, Hoffmann WE and Rand WM: Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Intern Med 14: 587-592, 2000.
39. Tomer G, Cohen IJ, Kidron D, et al. Prognostic factors in non-metastatic limb osteosarcoma: a 20-year experience of one center. Int J Oncol 15: 179-185, 1999.